- Home
- USIO vs HOWL Comparison
USIO vs HOWL Comparison
Compare USIO & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- HOWL
- Stock Information
- Founded
- USIO 1998
- HOWL 2017
- Country
- USIO United States
- HOWL United States
- Employees
- USIO N/A
- HOWL N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- HOWL Health Care
- Exchange
- USIO Nasdaq
- HOWL Nasdaq
- Market Cap
- USIO 36.6M
- HOWL 37.9M
- IPO Year
- USIO N/A
- HOWL 2021
- Fundamental
- Price
- USIO $1.56
- HOWL $0.80
- Analyst Decision
- USIO Strong Buy
- HOWL Strong Buy
- Analyst Count
- USIO 2
- HOWL 3
- Target Price
- USIO $5.00
- HOWL $8.33
- AVG Volume (30 Days)
- USIO 50.2K
- HOWL 236.0K
- Earning Date
- USIO 05-14-2025
- HOWL 05-08-2025
- Dividend Yield
- USIO N/A
- HOWL N/A
- EPS Growth
- USIO N/A
- HOWL N/A
- EPS
- USIO 0.12
- HOWL N/A
- Revenue
- USIO $82,931,840.00
- HOWL $1,143,000.00
- Revenue This Year
- USIO $16.14
- HOWL N/A
- Revenue Next Year
- USIO $13.51
- HOWL $733.33
- P/E Ratio
- USIO $13.17
- HOWL N/A
- Revenue Growth
- USIO N/A
- HOWL N/A
- 52 Week Low
- USIO $1.24
- HOWL $0.60
- 52 Week High
- USIO $2.92
- HOWL $5.73
- Technical
- Relative Strength Index (RSI)
- USIO 51.96
- HOWL 41.41
- Support Level
- USIO $1.56
- HOWL $0.80
- Resistance Level
- USIO $1.68
- HOWL $0.97
- Average True Range (ATR)
- USIO 0.09
- HOWL 0.08
- MACD
- USIO -0.01
- HOWL 0.01
- Stochastic Oscillator
- USIO 47.83
- HOWL 0.00
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.